Repligen Corporation (NASDAQ:RGEN) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Leerink John Kreger - William Blair Matt Hewitt - Craig Hallum Operator Good day, and welcome to the Repligen Corporation's Third Quarter 2020 Earnings Conference Call. My name Danielle, an ...

Repligen Corporation (NASDAQ:RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda - SVB Leerink LLC Tycho Peterson - JPMorgan Chase & Co. Jacob Johnson - Stephens Inc. John Kreger - William Blair & Company Matthew Hewitt - Craig-Hallum Capital Group LLC Operator G ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Juri ...

R Investor Presentation E ES 8 8 R 108 SUAO May 2020 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties which may cause our plans to change or actual results to differ materially from those anticipated. In particular, unforeseen events outside of our control ma ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other Jur ...

Repligen Corporation (NASDAQ:RGEN) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants Sondra Newman - Senior Director, IR Tony Hunt - CEO & President Jon Snodgres - CFO & Secretary Conference Call Participants Tycho Peterson - JPMorgan John Kreger - William Blair Dan Arias - Stifel Puneet Souda - SVB Leerink Jacob Johnson - Stephens Inc. Paul Knight - Janney, Montgomery, Scott Brandon Couillard - Jefferies Matt Hewitt - Craig-Hallum Ram Selvaraju - H.C. Wainwright Operator Good day ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Securities registered pursuant to Section 12(g) of the Act: None OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as speci ...

Repligen Corp. (NASDAQ:RGEN) Q4 2019 Earnings Conference Call February 20, 2020 8:30 AM ET Company Participants Sondra Newman - Senior Director, IR Anthony Hunt - CEO & President Jon Snodgres - CFO & Secretary Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company Puneet Souda - SVB Leerink Ruizhi Qin - JPMorgan Chase & Co. Paul Knight - Janney Montgomery Scott John Kreger - William Blair & Company Matthew Hewitt - Craig-Hallum Edward Marks - H.C. Wainwright & Co. Jacob Johnson - Stephens In ...

Repligen Corporation November 2019 Investor Presentation 2 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties which may cause our plans to change or actual results to differ materially from those anticipated. In particular, unforeseen events outside of our cont ...

Financial Data and Key Metrics Changes - The company reported revenues of $69.4 million for Q3 2019, reflecting a growth of 42% at constant currency and 28% organic growth [30][31] - Adjusted operating income increased by 34% year-over-year to $15.1 million, with adjusted EPS rising 44% to $0.26 per fully diluted share [30][42] - The company raised its full-year revenue guidance to $267 million to $270 million, indicating growth of 38% to 39% [11][46] Business Line Data and Key Metrics Changes - Direct filtration and chromatography businesses experienced organic growth of over 40% for both the quarter and year-to-date [19][31] - C Technologies contributed approximately $7 million in revenue for Q3 and is on track to meet its target of $16 million to $17 million for the partial year [14][11] - The proteins business is expected to achieve over 15% growth for the year, marking the first such growth since 2015 [20][54] Market Data and Key Metrics Changes - North America accounted for 52% of direct product revenue year-to-date, with Asia Pacific growing at 44% and Europe at 26% [31] - Gene therapy represented 13% to 15% of total revenue, with expectations for growth as the market matures [64][88] Company Strategy and Development Direction - The company is focused on integrating C Technologies and expanding manufacturing capacity for filtration and chromatography products [12][15] - New product launches, particularly the TFDF technology, are seen as significant innovations in harvest clarification [17][76] - The company aims to maintain a long-term organic growth target of 10% to 15% [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong performance in Q4 despite tough comparisons from the previous year [72] - The company is optimistic about the gene therapy market's growth potential, although it remains cautious about specific growth rates for 2020 [66][74] - The integration of C Technologies is progressing well, with a dedicated sales team being established [99][100] Other Important Information - The company generated free cash flow of $33.5 million year-to-date, with cash and cash equivalents totaling $513.5 million as of September 30, 2019 [43][42] - Adjusted gross margin for Q3 was 56.1%, with expectations for modestly lower margins in Q4 due to strategic investments [34][35] Q&A Session Summary Question: Dynamics of the protein business and lower ligands demand - Management noted strong growth in growth factors offsetting lower ligands demand, with confidence in achieving 15% organic growth for proteins [54] Question: Cross-selling opportunities with C Technologies - A dedicated sales team for C Technologies is being built to drive process analytics sales, with expectations for close collaboration with the existing sales force [56][58] Question: Overall market growth and share taking - The company has maintained a high growth rate, particularly in filtration and chromatography, with strong order demand [60][61] Question: Sustainability of gene therapy revenue - Gene therapy currently accounts for 13% to 15% of total revenue, with potential for growth as the market matures [64][66] Question: Integration progress of C Technologies - The integration is focused on building out the commercial organization, with no immediate revenue synergies expected in 2019 [100][101] Question: Capacity build-out priorities - The company is prioritizing capacity build-out for OPUS, ATF, and Spectrum businesses to meet strong demand [110][111]